Amidst ESA Upheaval, FDA Used Mircera Review To Outline Trial “Wish List”
FDA's review of Roche's Mircera BLA became a forum for the agency to set forth a "wish list" for future development of erythropoietin stimulating agents that reflected the seismic upheavals in the conventional understanding of the safety of erythropoietin products
You may also be interested in...
Cochran Collaboration ESA Meta-Analysis Underscores Survival Risk
A meta-analysis of patient level data from over 10,000 clinical trial patients suggests that use of erythropoiesis-stimulating agents may have an adverse survival impact in the still-approved uses in supportive care for oncology
Roche Mircera Launch Blocked By Permanent Injunction
Ruling comes just ahead appeals-court hearing on epoetin follow-on.
The Future Of ESAs – Is It All CKD Now?
Takeda and Affymax revise Hematide program to stop development for chemotherapy-induced anemia and focus on anemia related to chronic kidney disease.